UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
Nantes, June 9th, 2025, 8 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) informs its shareholders and the market of the update on the terms of the Combined General Meeting scheduled for 25 June 2025 (the 'General Meeting').
In preparation of the General Meeting, OSE Immunotherapeutics has formally submitted to the President of the Nantes Commercial Court a request to extend the date of the General Meeting.
The purpose of this approach is to ensure that the General Meeting is held in a regular and transparent manner and that shareholders are properly informed. It is in response to requests made by some of the Company's shareholders, in a context marked by the filing, by a group of shareholders acting in concert, of several resolutions aimed at substantially changing the composition of the Board of Directors.
Furthermore, the communication of these resolutions to the market did not occur in a timely manner nor under conditions ensuring, at this stage, that shareholders are fully and fairly informed or that the General Meeting is properly or regularly held.
In this respect, the resolutions presented by the group of shareholders acting in concert and which have not been approved by the Board of directors are not identified clearly enough on the voting form posted on the Company's website on June 4th, 2025.
The Company indicates that the resolutions of this group of shareholders, on which the Board of Directors recommends voting against, are renumbered A to K (instead of resolutions n°35 to 44). Apart from this renumbering, all the resolutions remain unchanged.
An amended convening notice will be published in the official legal bulletin.
The voting form along with the preparatory documents for the General meeting required by Article R. 22-10-23 of the French Commercial Code, as amended to include this renumbering, are available on the Company's website: https://www.ose-immuno.com/assemblees-generales/.
OSE Immunotherapeutics considers that the current situation as described above and in the press release dated June 4th, 2025 raises significant legal uncertainties, which justify referring to the judge to extend the date of the General Meeting in order to secure the voting process and ensure that shareholders are consulted in an orderly fashion.
OSE Immunotherapeutics affirms its determination to protect the interests of all its shareholders and to defend the transparency and integrity of its governance, in compliance with the legal and regulatory framework.
OSE Immunotherapeutics will communicate in due course on the progress of this procedure.
ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext.
Additional information about OSE Immunotherapeutics assets is available on the Company's website: www.ose-immuno.com. Follow us on LinkedIn.
Contacts
Fiona Olivierfiona.olivier@ose-immuno.comSylvie Détrysylvie.detry@ose-immuno.com
French Media Contact FP2COMFlorence Portejoiefportejoie@fp2com.fr+33 6 07 768 283
U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@rooneypartners.com+1 212 223 0561
Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.
Attachment
EN_250509_Update GM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
39 minutes ago
- New York Times
European Union Unveils Fresh Sanctions on Russia, Including a Nord Stream Ban
The European Union's executive arm unveiled its latest package of sanctions against Russia, aiming to apply pressure to President Vladimir V. Putin by damaging the nation's energy and banking sectors. The sanctions proposed on Tuesday — which still need to be debated and passed by member states — would ban transactions with the Nord Stream pipelines, hoping to choke off future flows of energy from Russia into Europe. They would lower the price cap at which Russian gas can be purchased on global markets, hoping to chip away at Russian revenues. And they would hit both Russian banks and the so-called 'shadow fleet,' old tanker ships, often registered to other countries or not registered at all, that Moscow uses to covertly transport and sell its oil around the world to skirt energy sanctions. The new measures would blacklist a new batch of ships that are being used in this way. The proposal is the 18th sanctions package to come out of Brussels since Russia's full-scale invasion of Ukraine. Taken as a whole, the measures are a sweeping effort to threaten Russian economic might and morale at a critical juncture in the war. The announcement comes as peace talks between Russia and Ukraine stall. Despite pressure from the Trump administration to work toward a cease-fire, the latest round of talks between the two sides, earlier this month in Istanbul, created little result outside of another agreement to swap prisoners. Want all of The Times? Subscribe.
Forbes
43 minutes ago
- Forbes
Circle Stock To $300?
Representation of cryptocurrency and Circle logo displayed on a screen in the background are seen in ... More this illustration photo taken in Krakow, Poland on June 10, 2022. (Photo by Jakub Porzycki/NurPhoto via Getty Images) Circle Internet Group Inc (NYSE: CRCL), the issuer of the USDC stablecoin, has rapidly emerged as one of the market's most watched stories following its IPO. Currently trading around $115 — a significant increase from its IPO reference price of $31 — the company has attracted substantial institutional support and increasing public interest from investors. With the crypto-fintech sector gaining momentum and regulatory clarity becoming more apparent, many are now asking: could Circle ultimately reach $300 per share? Circle's current primary revenue source is derived from the yield produced by the reserves supporting USDC, which now has a circulating supply close to $60 billion. These reserves, mainly invested in short-term U.S. Treasuries, generate dependable, scalable interest income — providing a foundational revenue stream. In 2024, Circle reported over $1.5 billion in revenue, primarily from interest earned on these reserves. If USDC's circulation grows to $150–200 billion over the next three to five years — a feasible scenario given the surge in global demand for stablecoins — Circle's reserve income alone could reach $4–5 billion annually. In addition to passive income, Circle's product roadmap features enterprise-grade APIs for programmable payments, digital identity layers, FX rails, and on-chain treasury services. This infrastructure-first strategy positions Circle similarly to a 'Stripe for digital dollars.' With substantial traction in these services, Circle could generate $2–3 billion in additional revenue from software-like recurring sources. Combining this with reserve yield, total revenue could grow to $6.5–8 billion annually within five years. Circle's capital-light operational model allows it to scale profitably. Despite high partner distribution expenses — such as payments to Coinbase — its underlying margin profile remains robust. Over time, net margins in the range of 25–30% are likely as the business diversifies and gains more control over customer relationships. If net income reaches $1.8–2.4 billion, and Circle holds 300–350 million shares outstanding post-IPO, the company could achieve earnings per share (EPS) in the $6.00–8.00 range. At a price of $300 per share, Circle would have a market capitalization in the range of $45–50 billion. This would correspond to a price-to-earnings multiple of 40–50x, which is in line with the valuation of rapidly growing, high-margin fintech platforms — especially those developing enterprise infrastructure (e.g., Stripe, Adyen, or legacy Visa during its earlier growth phase). In this situation, Circle would be valued not just for growth, but for being a unique crypto-native company with strong compliance, significant partnerships (e.g., BlackRock, Visa), and a pivotal role in the tokenization of real-world assets. A share price of $300 for Circle is not merely a bullish aspiration — it represents a goal that illustrates the company's desire to become the digital financial infrastructure layer of the internet. To achieve this, Circle must increase the circulation of USDC, enhance its platform services, and demonstrate its ability to generate stable earnings at scale — all while maintaining regulatory credibility. If this vision becomes a reality, Circle won't just be a stablecoin company — it will be a fundamental component of the financial system of the future. In such a landscape, a price of $300 may not signify overvaluation, but rather a fair valuation. Investing in a single stock like CRCL carries risks. Conversely, the Trefis High Quality (HQ) Portfolio, which contains 30 stocks, has consistently outperformed the S&P 500 over the past four years. What's the reason for this? Overall, HQ Portfolio stocks have provided higher returns with lower risk compared to the benchmark index, resulting in a less volatile experience, as shown by HQ Portfolio performance metrics.
Yahoo
an hour ago
- Yahoo
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the 'Common Stock'), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company's Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol 'ERNA.' The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The new CUSIP number following the reverse stock split will be 114082 308. As a result of the reverse stock split, every 15 shares of the Company's Common Stock issued and outstanding will be automatically reclassified into one new share of Common Stock. The reverse stock split will not modify any rights or preferences of the shares of the Company's Common Stock. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards, as applicable, and warrants, as well as to the number of shares issued and issuable under the Company's equity incentive plans. The Common Stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the number of authorized shares of Common Stock or the par value of the Common Stock. The reverse stock split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on June 2, 2025 at a ratio in the range of 1-for-10 to 1-for-15, such ratio to be determined by the Board of Directors. The Company's Board of Directors approved the reverse stock split at the ratio of 1-for-15. No fractional shares will be issued in connection with the reverse stock split, and no cash or other consideration will be paid in connection with any fractional shares. Stockholders who otherwise would have held a fractional share after giving effect to the reverse stock split will instead own one whole share of the post-reverse stock split Common Stock. As of the date of this press release, the Company had 110,418,022 shares of Common Stock issued and outstanding, which it anticipates will result in approximately 7,361,201 shares of Common Stock issued and outstanding on a split-adjusted basis, without giving effect to any rounding for fractional shares. Computershare Inc. and its affiliate Computershare Trust Company, N.A., the Company's transfer agent (collectively, 'Computershare'), will act as the exchange agent for the reverse stock split. Stockholders of record holding certificates representing pre-split shares of the Company's Common Stock will receive a letter of transmittal from Computershare with instructions on how to surrender certificates representing pre-split shares. Stockholders should not send in their pre-split certificates until they receive a letter of transmittal from Computershare. Stockholders with book-entry shares or who hold their shares through a bank, broker, or other nominee will not need to take any action. Stockholders of record who held pre-split certificates will receive their post-split shares in book-entry form and will receive a statement from Computershare regarding their Common Stock ownership post-reverse stock split. Additional information about the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the 'SEC') on April 14, 2025, which is available at and on the Company's website at Alongside Ernexa's recent financings and corporate restructuring, the Company believes this reverse stock split is a key step in strengthening its financial foundation and maintaining access to the capital markets needed to advance its clinical programs. About Ernexa Therapeutics Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting. ERNA-101 is the company's lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company's initial focus is to develop ERNA-101 for the treatment of ovarian cancer. For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to the impact of the reverse stock split. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law. Media & Investor Relations Contact investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
